| Welcome to FierceLifeSci Weekly Digest, your Friday roundup of the biggest and most popular stories from each of our publications. | |
|
| This week's sponsor is Camargo Pharmaceutical Services. | |  | [Webinar] How to Use 505(b)(2) to Achieve Commercial Success
Wednesday, November 30 | 11am ET / 8am PT
This webinar will benefit Biotech and Pharmaceutical executives interested in learning more on strategies to achieve commercial success with 505(b)(2) drug development, which averages 3.5 years and costs $20M to NDA approval compared with 11.5 years and $2.6B for 505(b)(1). Reserve Your Spot Today! |
Top Stories Of The Week Monday, November 14, 2016 As Novartis execs admit that Alcon might not fit their long-term plans, the Swiss drugmaker is looking at a short-term boost for its Sandoz business: It's in talks to buy the U.S.-based generics maker Amneal for up to $8B. Tuesday, November 15, 2016 Roche has put together a cancer immunotherapy research network and committed up to $100 million to support collaborations between the 21 academic centers. Members of the network will share data, expertise and technology with a view to accelerating the progress of programs out of the lab and into the clinic. Tuesday, November 15, 2016 Teva is trying to clean the slate on its history of allegedly paying bribes in foreign countries and has put aside more than half a billion dollars to cover anticipated settlements with U.S. authorities. Wednesday, November 16, 2016 Years removed from a bruising bribery scandal in China, GlaxoSmithKline has been winning awards for its corporate behavior. But a new lawsuit filed in a U.S. federal court may bring the scandal back to the fore. Sunday, November 13, 2016 Gilead’s hep C sales are already taking a beating. And now, data show it could have some stiff competition coming its way from an AbbVie rival to its newest product in the field. Monday, November 14, 2016 Scientists at the University of Michigan figured out long ago how to coax stem cells to grow into miniature lungs. But when they attempted to transplant the organs into mice, they failed, because the miniature lungs lacked the maturity and structure needed to be able to facilitate breathing. So biologists at the university teamed up with biomedical engineers to develop a solution to the problem. Tuesday, November 15, 2016 It's no easy feat to take an experimental vaccine into a massive, 20,000-patient Phase III study in Asia and Latin America, but that's just what Takeda did this fall with its dengue shot. To get there, however, the company’s vax unit had to stoke up a global growth spurt. Friday, November 11, 2016 Diabetes players Dexcom and Tandem Diabetes Care are joining forces with digital health company TypeZero Technologies on a closed-loop system for blood glucose control. Wednesday, November 16, 2016 The European Medicines Agency has followed through on plans to update its guidance on first-in-human clinical trials in light of a fatality in a French study earlier this year. Resources Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. | 
